Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15064979 | 0.85 | CNR2 (1.00) | CNR2KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL9845802 | 0.76 | MEN1 (0.67) | CNR2KMT2AMEN1AOC3L3MBTL1 | |
| SCHEMBL9845804 | 0.76 | ALDH1A1 (0.75) | CNR2KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL5325778 | 0.75 | KMT2A (0.76) | CNR2KMT2AMEN1L3MBTL1NPSR1 | |
| SCHEMBL15087787 | 0.75 | CNR2 (0.71) | CNR2KMT2AMEN1AOC3L3MBTL1 | |
| SCHEMBL15064610 | 0.75 | CNR2 (1.00) | CNR2KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL15064314 | 0.74 | CNR2 (1.00) | CNR2KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL1432499 | 0.74 | AOC3 (1.00) | CNR2KMT2AMEN1AOC3L3MBTL1 | |
| SCHEMBL81937 | 0.73 | CNR2 (0.71) | CNR2KMT2AMEN1AOC3L3MBTL1 | |
| SCHEMBL6297588 | 0.73 | ALDH1A1 (0.81) | CNR2KMT2AMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001949-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-05 | — | — | US | disclosed |
| US-20130172388-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | UNIVERSITY OF PITTSBURGH -- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001949-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | CNR2, CNR1, GPR3 | CNR2 1/4885KMT2A 2167/4885MEN1 1834/4885 |
| US-20130172388-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | CNR2, CNR1, GPR3 | CNR2 1/4885KMT2A 2385/4885MEN1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.